REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA
Clinical trials for REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to tame resistant blood cancers
Disease control OngoingThis study is testing the safety and effectiveness of combining two existing drugs, nivolumab and lenalidomide, for patients with non-Hodgkin or Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal is to see if using these drugs together can bet…
Matched conditions: REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug, pevonedistat, when given with an existing drug, ibrutinib. It is for adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal i…
Matched conditions: REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Scientists test new drug duo in fight against stubborn lymphoma
Disease control OngoingThis early-stage study is testing the safety and best dose of two drugs, ibrutinib and lenalidomide, when given together. It is for adults whose B-cell non-Hodgkin lymphoma has come back or has not responded to previous treatments. The goal is to see if combining these drugs is s…
Matched conditions: REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New 'Living Drug' trial offers hope for patients with aggressive lymphoma
Disease control OngoingThis study is testing a new type of personalized cell therapy for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to better tar…
Matched conditions: REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC